Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels

G Pavlasova, M Borsky, V Svobodova, J Oppelt… - Leukemia, 2018 - nature.com
The use of the anti-CD20 antibody rituximab has improved the outcome of patients with
chronic lymphocytic leukemia (CLL). Rituximab was shown to act via various mechanisms …
被引用次数：47 相关文章

Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels

G Pavlasova, M Borsky, V Svobodova, J Oppelt… - Leukemia, 2018 - go.gale.com
The use of the anti-CD20 antibody rituximab has improved the outcome of patients with
chronic lymphocytic leukemia (CLL). Rituximab was shown to act via various mechanisms …

Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels

G Pavlasova, M Borsky, V Svobodova, J Oppelt… - …, 2018 - pubmed.ncbi.nlm.nih.gov
Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation
characterized by high CD20 levels Rituximab primarily targets an intra-clonal BCR …
[PDF] researchgate.net

[PDF][PDF] Rituximab primarily targets an intra-clonal BCR signaling proicient CLL subpopulation characterized by high CD20 levels

G Pavlasova, M Borsky, V Svobodova, J Oppelt… - 2018 - researchgate.net
The use of the anti-CD20 antibody rituximab has improved the outcome of patients with
chronic lymphocytic leukemia (CLL). Rituximab was shown to act via various mechanisms …
[PDF] academia.edu

[PDF][PDF] Rituximab primarily targets an intra-clonal BCR signaling proicient CLL subpopulation characterized by high CD20 levels

G Pavlasova, M Borsky, V Svobodova, J Oppelt… - 2018 - academia.edu
The use of the anti-CD20 antibody rituximab has improved the outcome of patients with
chronic lymphocytic leukemia (CLL). Rituximab was shown to act via various mechanisms …

[引用][C] Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.

G Pavlasova, M Borsky, V Svobodova, J Oppelt… - Leukemia, 2018 - europepmc.org
Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation
characterized by high CD20 levels. - Abstract - Europe PMC Sign in | Create an account …
[PDF] muni.cz

[PDF][PDF] Rituximab primarily targets an intra-clonal BCR signaling proicient CLL subpopulation characterized by high CD20 levels

G Pavlasova, M Borsky, V Svobodova, J Oppelt… - THE ROLE OF …, 2018 - is.muni.cz
The use of the anti-CD20 antibody rituximab has improved the outcome of patients with
chronic lymphocytic leukemia (CLL). Rituximab was shown to act via various mechanisms …
[PDF] academia.edu

[PDF][PDF] Rituximab primarily targets an intra-clonal BCR signaling proicient CLL subpopulation characterized by high CD20 levels

G Pavlasova, M Borsky, V Svobodova, J Oppelt… - 2018 - academia.edu
The use of the anti-CD20 antibody rituximab has improved the outcome of patients with
chronic lymphocytic leukemia (CLL). Rituximab was shown to act via various mechanisms …

Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels

G Pavlasová, M Borský, V Šandová, J Oppelt… - Leukemia, 2018 - is.muni.cz
The use of the anti-CD20 antibody rituximab has improved the outcome of patients with
chronic lymphocytic leukemia (CLL). Rituximab was shown to act via various mechanisms …